Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 7/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | PPARG | P37231 | 3/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.46 |
| ▸ | FABP2 | P12104 | 1/20 | 0.46 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5672815 | 0.88 | PPARA (0.65) | PPARACYP1A2CYP3A4CYP2C19MAPT | |
| SCHEMBL11283720 | 0.81 | CA1 (0.48) | CYP3A4MAPTALDH1A1MAPK1NPSR1 | |
| SCHEMBL2830535 | 0.79 | PPARA (0.48) | PPARACYP1A2CYP3A4CYP2C19MAPT | |
| SCHEMBL17186898 | 0.79 | PPARA (0.48) | PPARACYP1A2CYP3A4CYP2C19MAPT | |
| SCHEMBL3365142 | 0.78 | CA4 (0.39) | PPARACYP1A2CYP3A4CYP2C19MAPT | |
| SCHEMBL6212374 | 0.77 | PPARA (0.49) | PPARACYP1A2CYP3A4CYP2C19MAPT | |
| SCHEMBL8886588 | 0.76 | NQO1 (0.54) | CYP1A2MEN1KMT2ATSHRALDH1A1 | |
| SCHEMBL196705 | 0.75 | PPARA (0.57) | PPARACYP1A2CYP3A4CYP2C19MAPT | |
| SCHEMBL11641137 | 0.75 | PPARA (0.44) | PPARACYP1A2CYP3A4CYP2C19MAPT | |
| SCHEMBL8886704 | 0.74 | PPARA (0.46) | PPARACYP1A2CYP3A4CYP2C19MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1512397-B1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | INST MED MOLECULAR DESIGN INC (JP) | 2014-10-08 | — | — | EP | claimed |
| US-20100113770-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-05-06 | — | — | US | claimed |
| US-20050192269-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | THOMPSON RICHARD C (US) | 2005-09-01 | — | — | US | claimed |
| US-20040106598-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting Beta-amyloid peptide release and/or its synthesis by use of such compounds | THOMPSON RICHARD C (US) | 2004-06-03 | — | — | US | claimed |
| EP-1089980-A1 | COMPOUNDS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS | Elan Pharmaceuticals, Inc. (US) | 2001-04-11 | — | — | EP | claimed |
| WO-1999067221-A1 | COMPOUNDS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS | ELAN PHARMACEUTICALS, INC. (US) | 1999-12-29 | — | — | WO | claimed |
| US-4118583-A | ANTICOAGULANT, ANTICHOLINERGIC AGENTS | LABORATORIES OM SOCIETE ANONYME (CH) | 1978-10-03 | — | — | US | claimed |
| US-4060617-A | Esters of the ophyllinylacetic acid | Wulfing, Johann A. (DT) | 1977-11-29 | — | — | US | claimed |
| US-10434076-B2 | Use of 2,5-dihydroxybenzene derivatives for treating dermatitis | AmDerma Pharmaceuticals, LLC (US) | 2019-10-08 | — | — | US | disclosed |
| US-20190192474-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Skin Cancer | AmDerma Pharmaceuticals, LLC | 2019-06-27 | — | — | US | disclosed |
| US-20190192473-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Rosacea | AmDerma Pharmaceuticals, LLC | 2019-06-27 | — | — | US | disclosed |
| US-10278941-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of glioma | AmDerma Pharmaceuticals, LLC (US) | 2019-05-07 | — | — | US | disclosed |
| US-10278940-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of skin cancer | AmDerma Pharmaceuticals, LLC (US) | 2019-05-07 | — | — | US | disclosed |
| US-20180036265-A1 | Use of 2,5-Dihydroxybenzene Derivatives for Treating Dermatitis | ACTION MEDICINES, S.L. (ES) | 2018-02-08 | — | — | US | disclosed |
| US-RE32581-E | Certain substituted phenyl esters of nicotinic acid, compositions and methods of using same for treatment of hyperlipidemia | MERZ + CO. GMBH & CO. (DE) | 1988-01-19 | — | — | US | disclosed |
| US-4412998-A | ANTILIPEMIC | MERZ & COMPANY (DE) | 1983-11-01 | — | — | US | disclosed |
| US-4321268-A | Certain substituted phenyl esters of nicotinic acid, compositions and methods of using same | MERZ & CO. (DE) | 1982-03-23 | — | — | US | disclosed |
| US-4118583-A | ANTICOAGULANT, ANTICHOLINERGIC AGENTS | LABORATORIES OM SOCIETE ANONYME (CH) | 1978-10-03 | — | — | US | disclosed |
| US-4060617-A | Esters of the ophyllinylacetic acid | Wulfing, Johann A. (DT) | 1977-11-29 | — | — | US | disclosed |
| US-4060617-A | Esters of the ophyllinylacetic acid | Wulfing, Johann A. (DT) | 1977-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190192473-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Rosacea | CYP8B1, CYP1B1, CYP26B1 | PPARA 957/4885CYP1A2 4/4885CYP3A4 163/4885 |
| US-10278940-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of skin cancer | CYP8B1, CYP26B1, CYP24A1 | PPARA 2820/4885CYP1A2 52/4885CYP3A4 220/4885 |
| US-10434076-B2 | Use of 2,5-dihydroxybenzene derivatives for treating dermatitis | CYP24A1, CYP8B1, CYP26B1 | PPARA 1350/4885CYP1A2 46/4885CYP3A4 407/4885 |
| US-20180036265-A1 | Use of 2,5-Dihydroxybenzene Derivatives for Treating Dermatitis | CYP24A1, CYP8B1, CYP26B1 | PPARA 1350/4885CYP1A2 46/4885CYP3A4 407/4885 |
| US-20100113770-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | RELA, NFKBIA, NFE2 | PPARA 130/4885CYP1A2 855/4885CYP3A4 1664/4885 |
| US-20040106598-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting Beta-amyloid peptide release and/or its synthesis by use of such compounds | BACE1, APP, BACE2 | PPARA 1886/4885CYP1A2 3381/4885CYP3A4 3317/4885 |
| US-20190192474-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Skin Cancer | CYP8B1, CYP26B1, CYP24A1 | PPARA 2820/4885CYP1A2 52/4885CYP3A4 220/4885 |
| US-20050192269-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | BACE1, APP, BACE2 | PPARA 1738/4885CYP1A2 3219/4885CYP3A4 3056/4885 |
| US-10278941-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of glioma | ALDH1A2, IDH3A, IDH3B | PPARA 1634/4885CYP1A2 31/4885CYP3A4 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.